Impact of an effective multidrug-resistant tuberculosis control programme in the setting of an immature HIV epidemic: System dynamics simulation model

International Journal of STD and AIDS

Volumn 16, Issue 8, 2005, Pages 560-570

  Atun, Rifat A ^a   Lebcir, Reda ^a   Drobniewski, Francis ^b   Coker, Richard J ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

HIV; Multidrug resistant tuberculosis; Russia; System dynamics; Transmission model; Tuberculosis

Indexed keywords

ARTICLE; DISEASE TRANSMISSION; DRUG DEPENDENCE; EPIDEMIC; HEALTH PROGRAM; HEALTH PROMOTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MAJOR CLINICAL STUDY; MASS SCREENING; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; RUSSIAN FEDERATION; SHORT COURSE THERAPY; SIMULATION; TUBERCULOSIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; COMPUTER SIMULATION; HUMANS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 23944473618     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462054679124     Document Type: Article

References (53)

1. Drobniewski F, Balabanova Y, Ruddy M, et al. Rifampin and multiple drug resistant tuberculosis in the Russian civilian and prison sectors - dominance of the Beijing strain family. Emerging Infect Dis 2002;8:1320-6
2. Farmer P, Bayona J, Becerra M, et al. The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis 1998;2: 869-76
3. World Health Organization. Anti-Tuberculosis Drug Resistance in the World Second Report. Geneva: World Health Organization, 2000
4. Shilova MV, Dye C. The resurgence of tuberculosis in Russia. Philos Trans R Soc Lond 2001;356:1069-75
5. UNAIDS/WHO. AIDS Epidemic Update. Geneva: UNAIDS/WHO, 2001
6. Primary multidrug-resistant tuberculosis - Ivanovo Oblast, Russia, 1999. MMWR 1999;48:661-4
7. Coker R, Dimitrova B, Drobniewski F, et al. Tuberculosis control in Samara Oblast, Russia: institutional and regulatory environment. Int J Tuberc Lung Dis 2003;7:920-32
8. Turett GS, Telzak EE, Torian LV, et al. Improved outcomes for patients with multidrug-resistant tuberculosis. Clin Infect Dis 1995;21:1238-44
9. Wallace JM, Hansen NI, Lavange L, , et al., for pulmonary complications of HIV infection study group. Respiratory disease trends in the pulmonary complications of HIV infection study cohort. Am J Resp Crit Care Med 1997;155: 72-80
10. Rhodes T, Lowndes C, Judd A, et al. Explosive spread and high prevalence of HIV infection among injecting drug users in Togliatti City, Russian Federation: implications for HIV prevention. AIDS 2002;16:F25-31
11. Dye C, Williams BG, Espinal MA, Raviglione MC. Erasing the world slow strain; strategies to beat multi-drug resistant tuberculosis. Science 2002;295:2042-6
12. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003;348:119-28
13. Coker R. Multidrug-resistant tuberculosis: public health challenges. Trop Med Int Health 2004;9:25-40
14. Tahaoglou K, Torun T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001;345:170-4
15. Blower SM, Gerberding JL. Understanding, predicting, and controlling the emergence of drug-resistant tuberculosis: a theoretical framework. J Mol Med 1998;76:624-36
16. Blower SM, Small PM, Hopewell P. Control strategies for tuberculosis epidemics: new models for old problems. Science 1996;273:497-500
17. May RM, Anderson RM. The transmission dynamics of human immunodeficiency virus (HIV). Philos Trans R Soc Lond Ser B Biol Sci 1988;321:565-607
18. Forrester JW. Industrial Dynamics. Cambridge, MA: The MIT Press, 1961
19. Richardson GP, Pugh AL. Introduction to System Dynamics with DYNAMO. Cambridge, MA: The MIT Press, 1981
20. Sterman JD. Business Dynamics. Systems Thinking and Modeling for a Complex World. Singapore: Mc-Graw Hill/Irwine, 2000
21. Vynnycky E, Fine PEM. Interpreting the decline in tuberculosis: the role of secular trends in effective contact. Int J Epidemiol 1999;28:327-34
22. Vynnycky E, Fine PEM. Lifetime risks, incubation period, and serial interval of tuberculosis. J Epidemiol 2000;152:247-63
23. Pitman R, Jarman B, Coker R. Tuberculosis transmission and the impact of intervention on the incidence of infection. Int J Tuberc Lung Dis 2002;6:485-91
24. Murray CLJ, Salomon JA. Modelling the impact of global tuberculosis control strategies. Proc Natl Acad Sci USA 1998;95:13881-6
25. Ford DN. A behavioural approach to feedback loop dominance analysis. System Dyn Rev 1999;15:3-6
26. Richardson GP. Loop polarity, loop dominance and the concept of dominant polarity. System Dynamics Review 1995;11:67-88
27. Dye C, Williams BG. Criteria for the control of drug-resistant tuberculosis. Proc Natl Acad Sci USA 2000;97:8180-5
28. Sonnenberg P, Murray CLJ, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African miner workers. Lancet 2001;358:1687-93
29. Pablos-Mendez A, Gowda DK, Frieden TR. Controlling multi-drug resistant tuberculosis and access to expensive drugs: a rational framework. Bull WHO 2002;80:489-95
30. Crassly N, Lowndes C, Rhodes T, Judd A, Renton A, Garnett GP. Modelling emerging HIV epidemics: the role of injection drug use and sexual transmission in the Russian Federation, China and India. Int J Drug Policy 2002;14:25-43
31. Dolan K, Wodak A, Hall W, Kaplan E. A mathematical model of HIV transmission in NSW prisons. Drug Alcohol Depend 1998;50:197-202
32. Dangerfield BC, Fang Y, Roberts CA. Model based scenarios for the epidemiology of HIV/AIDS: the consequences of highly antiretroviral therapy. Syst Dyn Rev 2001;17:119-50
33. Dangerfield BC, Roberts CA. Optimisation as a statistical estimation tool: an example in estimating the AIDS treatment free incubation period distribution. Syst Dyn Rev 1999;15:273-91
34. Isham B, Medley G. Models for Infectious Human Diseases: Their Structure and Relations to Data. Cambridge, UK: CUP, 1996
35. Dangerfield BC, Roberts CA. OR Work in HIV/AIDS. Birmingham, UK: Operational Research Society, 1994
36. Dye C, Garnett GP, Sleeman K, Williams BG. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Lancet 1998;352:1886-91
37. Murray M, Nardell E. Molecular epidemiology of tuberculosis: achievements and challenges to current knowledge. Bull WHO 2002;80:477-82
38. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974;99:131-8
39. Nunn P, Mungai M, Nyamwaya J, et al. The effect of human immunodeficiency virus type-1 on the infectiousness of tuberculosis. Tuberc Lung Dis 1999;75:25-32
40. Wallgren A. The time table of tuberculosis. Tubercle 1948;29:245-51
41. Rieder HL. Epidemiologic Basis of Tuberculosis Control. Paris: International Union Against Tuberculosis and Lung Disease, 1999
42. Styblo K. Epidemiology of Tuberculosis: Selected Papers. The Hague: Royal Netherlands Tuberculosis Association, 1991
43. National Tuberculosis Institute Bangalore. Tuberculosis in a rural population of South India: a five year epidemiological study. Bull WHO 1974;51:473-88
44. Toman K. Tuberculosis Case-Finding and Chemotherapy: Questions and Answers. Geneva: World Health Organization, 1979
45. Suarez PG, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2003;359:1980-9
46. Slutkin G, Schecter GF, Hopewell P. The results of 9-month isoniazid-rifampin therapy for pulmonary tuberculosis under program conditions in San Francisco. Am Rev Respir Dis 1988;138:1622-4
47. Medical Research Council Tuberculosis Chemotherapy Trials Committee. The treatment of pulmonary tuberculosis with isoniazid. BMJ 1952;2:735-46
48. Porco TC, Small PM, Blower SM. Amplification dynamics: predicting the effect of HIV on tuberculosis outbreaks. J Acquir Immune Defic Syndr 2001;28:437-44
49. Alland D, Kalkut GE, Moss AR, et al. Transmission of tuberculosis in New York city: an analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994;330:1710-16
50. Small PM, Hopewell P, Singh SP, et al. The epidemiology of tuberculosis in San Francisco: a population-based study using conventional and molecular methods. N Engl J Med 1994;330:1703-9
51. Coker R. Should tuberculosis programmes invest in second-line treatments for multidrug resistant tuberculosis (MDRTB)? Int J Tuberc Lung Dis 2002;6:649-50
52. Farmer P, Bayona J, Becerra M, Furin J, Henry C, Hiatt H. The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis 1998;2:869-76
53. Sterling TR, Lehman HP, Frieden RT. Impact of DOTS compared with DOTS plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis. BMJ 2003;326:574-9